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Developing countries (DCs) and developed countries 
have geographic, economic, and social differences. 
The prevalence and incidence of epilepsy are higher 
in DCs than in developed countries. However, 
within DCs, given the high incidence of epilepsy, 
the prevalence is relatively low, which may be due 
to high mortality for people with epilepsy (PWE). 
Neurocysticercosis is one of the main causes of 
symptomatic epilepsy in many DCs. Prognosis in 
DCs seems similar to that in developed countries. 
Because phenobarbital and phenytoin are available 
and inexpensive, they are the drugs most often used 
in DCs. The cost of newer antiepileptic drugs and 
the limited availability of resources for epilepsy care 
in DCs mean that care for PWE in DCs is marginal-
ized and that many people receive no pharmacologic 
treatment. The most cost-effective way to decrease 
the treatment gap in DCs would be to deliver the epi-
lepsy services through primary health care.
Introduction
There is no established convention for the designation of 
“developed” and “developing” countries in the United 
Nation system. The World Bank [1] defi nes developing 
countries (DCs) according to the annual gross national 
product (GNP). Categorization includes low-income 
countries (GNP per capita up to US $735), lower-middle-
income countries (GNP per capita US $736–$2935), 
and upper-middle-income countries (GNP per capita US 
$2936–$9075). The socioeconomic structure in DCs is 
marked by profound contrasts based on within-country 
income. A small percentage of the population has access 
to institutions (frequently privately owned) that are 
equipped with the latest and most sophisticated methods 
of diagnosis, which can offer state-of-the-art service. Most 
people in DCs suffer the effects of poverty, illiteracy, and 
malnutrition and must seek health care from a limited 
number of public institutions that cannot provide optimal 
services because of economic and administrative limita-
tions. Infectious and parasitic diseases remain among the 
leading causes of mortality in DCs [2].
Epilepsy is one of the most common serious disorders 
of the brain, affecting about 50 million people worldwide. 
It accounts for 1% of the global burden of disease, 80% of 
which is in the developing world, and in some areas 80% 
to 90% of people with epilepsy (PWE) receive no treatment 
at all [3]. This phenomenon is known as the treatment gap 
(TG). Major advances in understanding the natural history 
and social consequences of epilepsy have been made in 
recent decades, and there have been major improvements 
in its diagnosis and treatment. There is little information 
on these topics in DCs, and even when information is 
available, comparison across studies is diffi cult because of 
varying defi nitions and methodologies [2].
Information regarding available resources for care of 
PWE is insuffi cient not only in the developing world but 
in developed countries. Lack of information concerning 
existing resources is a major impediment for policymak-
ers at local, national, and international levels trying to 
plan appropriate services for epilepsy care. On the whole, 
there are signifi cant inequities within regions and income 
groups of countries, with low-income countries having 
meager resources [3].
Prevalence and Incidence
During the last two decades of the 20th century, there 
were numerous studies concerning the prevalence of epi-
lepsy in DCs. Lifetime prevalence ranged from 3.7 to 57 
per 100,000 person-years [2]. This wide variation was 
due in part to differences in study methodology. Many 
studies did not provide clear defi nitions, and age-adjusted 
prevalence or age-specifi c prevalence (a requisite to cal-
culate age-adjusted rates) was not provided. Therefore, it 
was impossible to compare incidence or prevalence across 
studies in DCs or with studies in the developed world. 
Over the past 5 years, there have been several reports 
regarding the frequency of epilepsy in DCs (Table 1). The 
reported prevalence is now more consistent because the 
methodology is frequently based on the recommenda-
tions of the International League Against Epilepsy (ILAE) 
Commission on Epidemiology and Prognosis [2]. The 
prevalence of active epilepsy in DCs ranges from 3.8 to 
15.4 per 1000 person-years (Table 1). The differences are 
in part related to different study designs and differences 
regarding the defi nitions of active epilepsy. Some stud-
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ies require two or more unprovoked seizures in the year 
before the index date to be considered “active epilepsy” 
[4–5,8••]; others use a 2-year period [9] or 5-year period 
[10•,11–15,16•,17•]. Limiting assessment to studies that 
provide information for age-adjusted rates (Table 1), the 
average age-adjusted prevalence of active epilepsy is 8.5 
per 1000 people. A Brazilian study reported a higher 
prevalence of epilepsy in more deprived social classes 
(7.5/1000) than in the less deprived (1.6/1000) [9••].
Incidence studies require surveillance of a population of 
adequate size over a suffi ciently long period of time to assure 
stable estimates of frequency. As a result, incidence studies are 
expensive and relatively few reports are available for total pop-
ulations. In developed countries, the age-adjusted incidence 
of epilepsy ranges from 24 to 53 per 100,000 [18]. In DCs, 
based on two studies carried out in South America in the past 
decade, incidence ranged from 114 to 190 per 100,000 [2], 
which is considerably higher than that reported in industrial-
ized countries. Recent studies confi rm the high incidence: a 
hospital-based study of children in Tunisia reported the inci-
dence of fi rst unprovoked seizures to be 102 per 100,000 [19]. 
A population-based study carried out among children in Kenya 
reported the incidence of epilepsy (two or more unprovoked 
seizures) to be 187 per 100,000 [8••]. In a population-based 
study among all ages in Honduras [14], the incidence of non-
febrile seizures was 92.7 per 100,000 (Table 1). Because of 
Table 1. Epidemiologic profi le of some developing countries
Study Country N
Prevalence, 
x 1000 Data Study design
Wang et al. [4] China 58,806 4.6* Treatment gap: 
63%
Door-to-door survey; 
community-based†
Birbeck and 
Kalichi [5]
Zambia 55,000 12.5*‡ — Door-to-door survey; 
community-based
Del Brutto et al. [11] Ecuador 2548 10.8§‡ — Door-to-door survey; 
community-based
Dent et al. [12] Tanzania 141,834 7.4§‡ — Door-to-door survey; 
community-based
Medina et al. [13] Honduras 7384 15.4§ Incidence: 
92.7/100,000; 
treatment gap: 53%
Door-to-door survey; 
community-based
Ndoye et al. [6] Senegal 480,000 14.2* Treatment gap: 
23% 
Door-to-door survey; 
community-based†
Carpio et al. [22] Ecuador 420 — SMR: 6.3 Prospective; hospital-based
Chen et al. [35] Taiwan 263 — SMR: 3.7 Prospective; hospital-based
Calisir et al. [14] Turkey 2116 8.5§‡ — Community-based
Ding et al. [23] China 2455 — SMR: 3.9 Prospective; population-based
Melcon et al. [10•] Argentina 70,000 3.8§ — Community-based
Noronha et al. [9••] Brazil 96,300 5.4¶ Treatment gap: 
37.6%
Door-to-door survey; 
community-based†
Mungala-Odera 
et al. [7]
Kenya 108,896 11*‡ Incidence: 
187/100,000
Population-based; > 
2 unprovoked seizures 
in children
Tran et al. [15] Laos 23,788 7.7§ — Door-to-door survey; 
community-based
Bielen et al. [17•] Croatia 212,069 5.0§‡ — Health institution–based
Kaiser et al. [24] Uganda 61 — SMR: 7.2 Prospective; population-based 
Edwards et al. [8••] Kenya 253,291 4.5*‡ Treatment gap: 
70.3%
Community-based; children 
< 6 y were excluded
Tuan et al. [16•] Vietnam 47,269 4.4§‡ — Door-to-door survey; 
community-based†
*Active epilepsy was defi ned as at least two unprovoked seizures in the preceding year.
†These studies were part of the Global Campaign Against Epilepsy demonstration projects supported by the International League Against 
Epilepsy, International Bureau for Epilepsy, and World Health Organization.
‡Age-adjusted.
§Active epilepsy was defi ned as at least two unprovoked seizures in the preceding 5 years.
¶Active epilepsy was defi ned as at least two unprovoked seizures in the preceding 2 years.
SMR—standardized mortality ratio.
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the broader case-inclusion criteria and uncertainty regarding 
age-specifi c distribution in these incidence studies, there is no 
way to compare the results.
Studies from developed countries show a consistent 
pattern suggesting that the onset of epilepsy occurs at both 
extremes of life [18]. However, the incidence in DCs is 
highest among young and middle-aged adults [2], perhaps 
as a manifestation of prevalent diseases in these age groups, 
including conditions such as the parasitic diseases that are 
endemic in these countries and brain injury infections.
A recent population-based study was performed to 
determine the incidence of fi rst unprovoked seizures or 
newly diagnosed epilepsy in a low-income, predominantly 
Hispanic population in Northern Manhattan, New York 
City [20••]. Lower income was associated with higher inci-
dence (164/100,000). Interestingly, this incidence is similar 
to those reported in comparable populations of DCs.
Prognosis
The prognosis of epilepsy can be measured in several 
ways: according to the risk of recurrence after a seizure, 
probability of remission, risk of relapse after drug with-
drawal, and mortality in PWE [21]. In DCs, the prognosis 
of epilepsy might be different from that in industrialized 
countries, but few studies of natural history allow com-
parisons [2]. Methodologic shortcomings also contribute 
to the uncertainties.
Around the world, the prognosis of epilepsy is favor-
able for most PWE. Mortality in PWE is increased in 
DCs as well as developed countries [22–24]. The absolute 
mortality is higher in DCs, which may in part explain 
why prevalence tends to be only slightly higher (8.5/1000) 
than in developed countries. In contrast, the incidence of 
epilepsy is two to three times higher than in industrial-
ized countries. Because increased mortality only accounts 
for a small portion of the defi cit of cases, the most likely 
explanation for the similarity of the prevalence rates is 
spontaneous remission in many people [21].
About 70% of PWE achieve long-term remission— 
most within 5 years of diagnosis [21]. In DCs, after a 
fi rst unprovoked seizure, the risk of recurrence is 33% to 
37%, which is similar to that among developed countries 
[25–27]. Studies from DCs show that epilepsy secondary 
to underlying structural causes [26] or with an abnormal 
electroencephalogram confers the worst prognosis [27]. 
The type of seizure (generalized or partial) and the drug 
treatment used seem not to affect prognosis. Calcifi cations 
on CT suggest a probable parasitic or infectious etiology 
and do not increase the risk of recurrence [28,29]. No 
studies of the prognosis of epileptic syndromes have been 
published from DCs.
Prognosis for seizure recurrence 
in patients with neurocysticercosis
Neurocysticercosis (NC) is endemic in some DCs but is 
now becoming a serious health problem in industrialized 
nations with high immigrant populations. Acute symp-
tomatic seizures are the main clinical manifestation of 
NC [28]. Based on prospective studies, NC generally has 
an overall favorable prognosis in terms of seizure control 
and seizure remission [28,29]. A Brazilian study con-
fi rms the good prognosis of parenchymal NC [29]. The 
authors point out that infl ammatory processes related to 
parasitic infection, death, degeneration, and calcifi cations 
in the brain of the host do not signifi cantly aggravate the 
cognitive defi cits observed in medically refractory mesial 
temporal lobe epilepsy.
A clinical trial regarding treatment with cysticidal 
drugs for patients with epilepsy due to NC did not fi nd 
a reduction in the number of seizures overall but did 
report a reduction in the number of generalized seizures 
in patients treated with albendazole [30]. Recent clinical 
trials have shown that treatment with cysticidal drugs 
does not modify the long-term seizure outcome in patients 
with NC [31••,32,33••]. Even worse, cysticidal therapy 
may have an adverse effect with respect to seizure control, 
encephalopathy, recurrent hospital admissions, calcifi ca-
tion of lesions, and cost of treatment [34•].
Interpreting the risk of seizures after NC is diffi cult 
because of the failure to distinguish acute symptomatic 
seizures from epilepsy. These diffi culties are increased in 
patients who have mixed forms, including active, tran-
sitional, and calcifi ed lesions. Further studies should be 
performed to estimate recurrence risk in patients with 
probable unprovoked seizures with or without calcifi ca-
tions but without other lesions versus patients with acute 
seizures due to transitional cysts.
Mortality
In developed countries, the overall mortality associated 
with epilepsy is two to three times greater than that found 
in the general population [21]. In DCs, it is almost impos-
sible to ascertain the number of deaths due to epilepsy 
because incidence studies are diffi cult to conduct, death 
certifi cates are unreliable, autopsies are not easy to obtain, 
and the cause of death is not usually known with certainty 
[2]. There are few reliable coroners’ reports, and many of 
the reports that are available are incomplete. Migration 
makes large, prospective, population-based mortality 
studies of epilepsy diffi cult to carry out [22,35].
Few studies of mortality in PWE have been performed 
in DCs. It seems that mortality in PWE in these coun-
tries is generally higher than that reported in developed 
countries. The standardized mortality ratio (calculated 
by comparing the observed number of deaths in the epi-
lepsy cohort with that expected in the general population) 
ranges from 3.7 [35] and 3.9 [23] in prospective, cohort, 
population-based studies in China to 6.3 in a prospective 
cohort study in Ecuador [22] and 7.2 in a population-
based study in Uganda [24]. These ratios are higher than 
the twofold to threefold increases reported in developed 
countries. It is not possible to generalize these mortality 
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numbers to the general population because they were 
obtained from selected populations. Prospective studies 
are needed in DCs to follow a large cohort with new-
onset epilepsy for a defi ned length of time to determine 
the mortality. These studies are expensive and diffi cult to 
perform, but they are necessary if we are to understand 
the increase of mortality in epilepsy in DCs.
Etiology
In DCs, analytical epidemiologic studies designed to 
establish associations and determinants of epilepsy have 
been scarce. Comparing results of studies of etiology is 
diffi cult because of differences in defi nitions and lack of 
diagnostic criteria [36]. Most studies lack information on 
the latency between the fi rst acute symptomatic seizure 
(if any) and the fi rst unprovoked seizure, age at onset of 
seizures, and age at diagnosis. In studying etiology, it is 
preferable to use incident cases instead of prevalent cases 
because with prevalent cases one cannot distinguish the 
potential etiologic factors that preceded the onset of epi-
lepsy from those that occurred after the disease developed. 
Cause and effect become confused. Despite the lack of 
uniform criteria, newly available information shows that 
the rates of idiopathic/cryptogenic epilepsy (60%–70%) 
and symptomatic epilepsy (30%–40%) remain constant 
both in developing and developed countries [2].
Etiology and risk factors for epilepsy vary with age 
and geographic location. Congenital, developmental, and 
genetic conditions are mostly associated with epilepsy 
in childhood, adolescence, and early adulthood. Head 
trauma, central nervous system infections, and tumors 
may occur at any age and may lead to epilepsy, but tumors 
are more common after age 40. Cerebrovascular disease is 
the most common risk factor for epilepsy in people older 
than 60. In some parts of DCs, endemic infections such as 
malaria, NC, paragonimiasis, and toxocariasis are associ-
ated with epilepsy [36,37,38••].
Studies of highly selected patients with seizures in 
neurologic services of hospital settings from some DCs 
reported NC to be the main cause of epilepsy, accounting 
for 30% to 50% of cases [11,13]. It is likely that most peo-
ple with NC have acute symptomatic seizures that do not 
necessarily evolve into epilepsy. This is one of the reasons 
that epilepsy is overdiagnosed in some studies in which 
there is no differentiation between seizures and epilepsy 
[36]. In about two-thirds of patients with acute symptom-
atic seizures due to NC, the seizures do not recur [28].
In a recent study of 212 PWE in a rural sub-Saharan 
Africa area endemic for porcine cysticercosis using CT 
to facilitate the diagnoses, 2.4% were identifi ed as hav-
ing defi nitive NC and 11% had lesions highly suggestive 
of NC [39••]. A study in India to determine the etiologic 
role of NC in a hospital-based sample in 1026 patients 
with epilepsies divided results according to the ILAE’s 
epidemiologic criteria [36]. NC was diagnosed on imag-
ing studies in 59% of those with a single seizure but only 
2.0% with prevalent epilepsy. These results confi rm the 
necessity of differentiating between acute seizure and 
recurrent unprovoked seizures (epilepsy).
A study in rural Ecuador concluded that NC is associ-
ated with one in three cases of epilepsy and was possibly 
the cause of the excessive amount of epilepsy in that 
population [11]. However, only three of 24 PWE (8%) 
had “defi nitive” NC. A community survey in Peru showed 
that seroprevalence (using the enzyme-linked immuno-
electrotransfer blot [EITB] assay) was positive in 24.2% 
(200/825); 38.5% of individuals (15/39) with seizures in 
this community had lesions compatible with NC on CT 
[40]. The authors concluded that brain CT abnormalities 
compatible with NC were more frequent in individuals 
with seizures and in those with a positive EITB assay for 
cysticercosis. Most of the patients who were diagnosed 
with NC had only calcifi cations (half of them had just 
one calcifi cation). However, brain calcifi cations are not 
synonymous with NC, and the small number of people in 
these studies do not allow generalizations. Some authors 
have reported an association between seizures and NC 
based on positive serum antibodies to Taenia solium/cys-
ticercosis [41]; unfortunately, the presence of antibodies 
may indicate only previous exposure to or infection with 
the parasite but not necessarily a brain infection.
NC and epilepsy are common in most DCs. Because of 
the high prevalence of both conditions, some of the coex-
istence of the two conditions could occur by chance alone 
[29]. New interesting studies have suggested that perile-
sional edema is associated with episodic seizure activity in 
patients with calcifi ed NC [42•], but it is not clear whether 
this edema is causal or a consequence of the seizure. An 
irritative zone in the temporal lobe is more relevant in 
determining the severity, symptomatology, and frequency 
of seizures than the number and location of calcifi cations 
[43•]. These fi ndings provide a better understanding of 
the relationship between NC and epilepsy.
Treatment
The choice of drug in most DCs depends on availability 
and cost. Phenobarbital (PB) and phenytoin, which are 
commonly available and inexpensive, are the drugs that 
are used most often in DCs [2]. Widely available but more 
expensive choices include carbamazepine and sodium 
valproate. The administration of all of these antiepileptic 
drugs (AEDs) entails additional problems in DCs aside 
from side effects. Anemia and hepatitis are already associ-
ated problems in DCs; therefore, it may be impossible to 
differentiate problems of AEDs from concurrent illnesses. 
Malabsorption syndromes, malnutrition with hypopro-
teinemia, and hepatic dysfunction may interfere with the 
pharmacokinetics of AEDs [44].
Epilepsy is a controllable disorder in most people. 
About 60% to 70% of patients will become seizure free 
with AED therapy. Treatment does not need to be expen-
sive. The direct drug cost of treating a patient for a year 
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with PB could be as low as US $2.60 [45]. The World 
Health Organization (WHO) recommends PB as the 
treatment of choice for partial and tonic-clonic seizures 
in resource-restricted countries [3]. This policy has been 
questioned in the developed world, because PB is thought 
to be less well tolerated than other AEDs [45]. Since PWE 
in developed countries are seldom prescribed PB because 
of its toxicity, some feel it would be unethical to recom-
mend its use in DCs. Nonetheless, if the drug is not as 
toxic as it is believed to be, it might be used more widely 
in the developed world [46]. PB has many favorable fea-
tures: broad-spectrum effi cacy against all seizure types 
other than absences; seizure freedom rates comparable 
to those associated with modern drugs; long half-life 
compatible with once-daily dosing; and, especially, low 
cost. Disadvantages include enzyme induction, sedation, 
adverse cognitive and behavioral effects (particularly in 
children), and risk of fetal malformations in offspring of 
PWE [46].
Controlled trials in DCs suggest that few differences 
in effi cacy exist between PB and other established AEDs. 
Most studies in DCs do not show excess neuropsychologi-
cal toxicity of PB compared with other anticonvulsants, 
possibly because dosages in these studies tended to be 
lower than those used in developed countries or because 
lack of options make people less willing to report side 
effects [45]. A study of children in Bangladesh [47•] found 
no signifi cant difference in behavioral problems such as 
restlessness and hyperactivity between PB and carba-
mazepine (7% vs 11%) and no signifi cant difference in 
psychological and behavioral assessments after 1 year. 
Among children who completed a 1-year follow-up, 47.5% 
of those on PB and 60% of those on carbamazepine were 
seizure free for the most recent 6 months. Nonetheless, 
this study has limitations, including an open-label design 
and low power to detect potentially important differences 
in seizure outcome and behavioral test scores. A large 
community-based intervention study at the primary care 
level in rural China enrolled 2455 patients with convul-
sive epilepsy [48•]. Physicians with basic training could 
treat epilepsy patients with PB, with benefi cial effects for 
most patients with convulsive seizures. Few cognitive or 
behavioral adverse events were noted, but formal psycho-
metric testing was not done.
Newer AEDs, including oxcarbazepine, lamotrigine, 
gabapentin, topiramate, levetiracetam, and pregabalin, 
are available, locally manufactured, and sold in very few 
DCs with a developed pharmaceutical industry. However, 
because many of these drugs are still unaffordable to most 
people in DCs, the clinician should always consider cost 
before prescribing them [2].
Treatment gap
According to the WHO, about 80%of the 35 million PWE 
who live in DCs receive no treatment at all [3]. As a conse-
quence, they experience morbidity related to seizures and 
the psychosocial consequences of stigma and discrimi-
nation. Unfortunately, most of these people—many of 
whom are children—could have their seizures completely 
controlled and return to a normal life by taking a single 
daily dose of a drug that costs less than $3 (£1.50; €2.20) 
each year [45].
The TG is defi ned as the number of people with active 
epilepsy not on treatment or on inadequate treatment; 
it is expressed as a percentage of the total number with 
active epilepsy [49]. The gap is reported to be infl uenced 
by various factors, including lack of access to or knowl-
edge of AEDs, poverty, cultural beliefs, stigma, poor 
health delivery infrastructure, and shortage of trained 
professionals [49]. A wide variation of the TG has been 
reported over the past 5 years [5,7,9••,11,14], ranging 
from 23% to 70% (Table 1). In a systematic review of the 
TG in DCs, Mbuba et al. [50••] observed a high degree 
of heterogeneity and inconsistency between studies. The 
overall estimate of the TG was 56%, which is much lower 
than the 80% to 90% that is widely quoted in many stud-
ies [3,49]. The variation in estimates may be explained by 
nonuniform methods used to estimate the TG as well as 
the diverse study populations. The TG was mainly attrib-
uted to inadequate skilled manpower, cost of treatment, 
cultural beliefs, and unavailability of AEDs.
In addition to the TG, a wide gap exists between the 
need for AEDs and their availability. Only 20% of the 
potential market for AEDs is in developed countries, but 
these countries receive more than 80% of the total global 
supply of AEDs. This means that DCs receive only 10% to 
20% of AEDs, but they have a greater need for them [51].
Surgical treatment
Surgery for epilepsy has been proved feasible and cost-
effective in DCs [52•]. However, it is available in only 
13% of low-income countries, versus 66% of high-income 
countries [3]. The success of epilepsy surgery depends on 
the accurate identifi cation of good surgical candidates 
and the selection of the best candidates based on the 
available resources and technologies without endangering 
safety. Selecting patients amenable to surgery with the use 
of limited resources is a key issue in DCs. In this regard, 
training physicians capable of compiling a good history 
and referring appropriate patients to the epileptologist is 
critical [52•]. Most patients are seen and followed at pri-
mary and secondary care facilities, where the attending 
physicians may have limited knowledge of current con-
cepts in managing epilepsies. As an important step in the 
care of medically refractory patients with epilepsy, appro-
priate primary health care strategies should be defi ned and 
introduced in DCs to educate physicians on the diagnosis 
of epilepsy and various management strategies.
Nowadays, there is increasing enthusiasm for devel-
oping epilepsy surgery programs in DCs. For example, 
in Uganda, a facility was developed for the treatment of 
intractable temporal lobe epilepsy that functions within 
the technologic and expertise constraints of a severely 
low-resource area [53•]. This program relies on partner-
324  I  Epilepsy
ship with epilepsy professionals and training of local staff. 
The aim of the program was to evaluate the feasibility of 
an epilepsy surgery program in a resource-limited setting. 
The investigators used technology and expertise that was 
reasonably available and could function in a sustained 
manner in this setting.
Care
The Global Campaign Against Epilepsy: Out of the 
Shadows program was launched in 1997 “to improve 
acceptability, treatment, services and prevention of epi-
lepsy worldwide” [3]. The campaign is conducted by the 
WHO in partnership with the ILAE and the International 
Bureau for Epilepsy (IBE). The aim of the campaign is 
principally to reduce the TG by providing better infor-
mation about epilepsy and its consequences and to help 
governments and those concerned with epilepsy to reduce 
the burden of the disorder.
Many constraints and diffi culties hinder the provi-
sion of adequate epilepsy care in DCs. Some of the major 
stumbling blocks include poor community knowledge and 
awareness, cultural beliefs, stigma, poor economy, and 
the lack of drug supplies (due to logistics or the economy), 
infrastructure, and government resources [2]. Worldwide, 
there are large inequities in the cost of fi rst-line AEDs 
and the availability of resources for epilepsy care, with 
low-income countries having extremely limited resources. 
There is also inequity in the availability of diagnostic 
services in DCs. Although most new technologies are 
available in some DCs, they are often concentrated in 
only a few centers or major cities [2,3].
The most cost-effective way to decrease the TG in DCs 
would be to deliver epilepsy services through primary 
health care. DCs often lack personnel with neurologic 
expertise who can recognize and appropriately treat epi-
lepsy patients [54]. The ideal neurologist-to-population 
ratio is 1:100,000, and this ratio is not achieved in most 
DCs. The main tasks of the personnel in primary care set-
tings involved in epilepsy care should include follow-up 
and monitoring of treatment, maintenance and/or pre-
scription of AEDs, information and education of patients 
and caregivers, referral of PWE for specialist treatment, 
and case ascertainment [55]. Where resources are avail-
able, the care of epilepsy patients should be provided by 
a multidisciplinary team. Through more appropriate and 
timely use of these treatment modalities and better orga-
nization in the delivery of care, it is hoped that more PWE 
around the world can benefi t from effective treatment and 
live safer and more fulfi lling lives [3,4].
One of the main activities of the ILAE/IBE/WHO—
designed to help countries develop national programs on 
epilepsy—envisioned the initiation and implementation 
of demonstration projects with the ultimate goal of devel-
oping a variety of successful models of epilepsy control 
that could be integrated into the participating countries’ 
health care systems [3,51]. Demonstration projects have 
been carried in China [4], Togo [56], Brazil [9], Senegal 
[6], and Vietnam [17•].
From the epidemiologic perspective, epilepsy is a 
signifi cant cause of disability and disease burden in the 
world. Disability-adjusted life years (DALYs) have been 
proposed as an indicator of the health effects of health 
care systems and are used to evaluate the impact of mor-
tality and morbidity together [57]. Ding et al. [58] carried 
out a study to demonstrate the application of DALYs as an 
aid in health outcome measures to evaluate the epilepsy 
disease burden. The authors reported that the DALYs lost 
because of epilepsy was 2.08 per 1000 people, represent-
ing the epilepsy disease burden in rural China.
Conclusions
The studies examined in this article lead to a number of 
conclusions.
• The prevalence of epilepsy in DCs is about 
8.5/1000, which is similar to the rate in developed 
countries. The prevalence is low given the high 
incidence of epilepsy in DCs and may be due to the 
fact that mortality of PWE is higher than that of 
developed countries.
• The incidence of epilepsy in DCs (more than 
92/100,000) is higher, mainly in children, than in 
developed countries (40/100,000 to 70/100,000) 
and is probably related to a high prevalence of risk 
factors in poor countries, such as poor perinatal 
care, a higher frequency of head injury, and a high 
prevalence of infectious and parasitic diseases.
• The rates of idiopathic/cryptogenic (60%–70%) 
and symptomatic (30%–40%) epilepsy in DCs 
are similar in developed countries. However, the 
causes of epilepsy in the symptomatic group in 
DCs are different than in developed countries.
• It seems that the mortality rate from epilepsy is much 
higher in DCs than in industrialized countries.
• The risk of seizure recurrence in people with newly 
diagnosed epilepsy is similar in DCs and industri-
alized countries. There is an increased risk of early 
seizure recurrence in patients with symptomatic 
epilepsy and patients with an abnormal CT 
scan. These results are also comparable to those 
reported in industrialized nations.
• To establish risk factors and mortality for epilepsy in 
DCs, further prospective analytical studies are needed. 
New epidemiologic measures such as DALYs should 
be used to evaluate the epilepsy disease burden.
• Concerted multidisciplinary efforts concentrating 
on the risk factors (eg, enforcement of strict traffi c 
regulations and improvement in perinatal care) or 
the provision of specifi c protection (eg, vaccina-
tion) for preventable causes can help to decrease 
substantially the burden attributable to epilepsy.
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• PB may be less toxic than generally thought and might 
be considered more often to treat PWE in DCs.
• The most cost-effective way to decrease the TG 
in most countries would be to deliver epilepsy 
services through primary health care. Future 
research should estimate the TG coherently and 
develop sustainable interventions that will address 
the causes.
• The ILAE/IBE/WHO should pressure pharmaceu-
tical companies to reduce the cost of new AEDs 
in low-income countries. These organizations 
should make a major effort to bring new AEDs to 
low-income countries. Widespread epilepsy treat-
ment will be an extremely sound global investment 
toward the economic, social, and political well-
being of the world’s poor.
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